Company intelligence / Profile preview
RogCon
New Haven, Connecticut, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
RogCon is developing antisense oligonucleotide therapies targeting SCN2A gain-of-function mutations associated with rare epilepsies and related neurodevelopmental disorders. Lead program RC-222 has shown efficacy in animal models including improved survival and reduced seizures; all drug candidates are preclinical[1][2][4].
- Therapeutic areas
- NeurologyPsychiatry
- Modalities
- Antisense oligonucleotide
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Ionis PharmaceuticalsThe Florey Institute of Neuroscience and Mental HealthPrometheus Research
Beyond the preview
Go deeper on RogCon.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RogCon.